Information  X 
Enter a valid email address

Karolinska Development AB (pub (0P3C)

  Print   

Monday 16 October, 2017

Karolinska Development AB (pub

Karolinska Development's portfolio company Aprea announces first patient enrolled in clinical phase 1b/2 study with APR-246 for the treatment of esophageal cancer

YASTEST

a d v e r t i s e m e n t